ERBB2 and colorectal cancer: The second case involved a 41-year-old female with colorectal cancer and ErbB2 amplification (identified by FISH and NGS), who had previously received multiple lines of ErbB2-targeted therapies, including trastuzumab, pertuzumab, and a bispecific ErbB2 × 4-1BB agent.